Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RxGen and miRagen Therapeutics have received a Small Business Innovation Research (SBIR) grant of around $720,000 by the National Heart Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH).
Subscribe to our email newsletter
The grant will support continued preclinical research on microRNA targeting in cardiovascular disease and help to establish a novel model system of chronic heart failure.
The research aims to show the potential of miRNA regulation as a novel treatment for cardiac disease.
RxGen CEO Matthew Lawrence said the combination of RxGen’s in-vivo modeling capabilities and miRagen’s microRNA research expertise uniquely positions them to accelerate cardiac applications of microRNA therapeutics.